<DOC>
	<DOCNO>NCT00528931</DOCNO>
	<brief_summary>A Phase 1 , open-label , single-dose pharmacokinetic study subject Dupuytren 's contracture conduct one site United States . All subject receive single dose AA4500 0.58 mg , inject directly cord affect either metacarpophalangeal ( MP ) proximal interphalangeal ( PIP ) joint . Pharmacokinetic blood sample collect dosing , predetermine time point 24 hour dose , Day 7 , Day 30 . Efficacy safety assessment perform 30 day AA4500 0.58 injection . This study design part large clinical program , adult patient Dupuytren 's contracture palpable cord , data 2 pivotal Placebo-Controlled study ( AUX-CC-857 [ NCT00528606 ] AUX-CC-859 [ NCT00533273 ] ) 7 non-pivotal study evaluate .</brief_summary>
	<brief_title>A Pharmacokinetic Study AA4500 ( XIAFLEX™ , Proposed Name ) Subjects With Dupuytren 's Contracture</brief_title>
	<detailed_description />
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>Subjects diagnosis Dupuytren 's contracture , fix flexion deformity least one finger , thumb , contracture least 20° , great 100° MP ( 80° PIP ) joint , cause palpable cord . Had positive `` table top test , '' define inability simultaneously place affect finger ( ) palm flat table top . Were naive AA4500 treatment . Were judge good health . Had chronic muscular , neurological , neuromuscular disorder affect hand . Had receive treatment Dupuytren 's contracture within 90 day AA4500 injection MP PIP select , include surgery ( fasciectomy surgical fasciotomy ) , needle aponeurotomy/fasciotomy , injection verapamil and/or interferon select primary joint within 90 day first dose study drug . Had know recent history stroke , bleeding , disease process affect hand , medical condition , investigator 's opinion , would make subject unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Assessment AUX I and/or AUX II human plasma</keyword>
</DOC>